Changing Landscape of Diagnosis and Treatment of Multiple Myeloma

Thursday, November 16, 2023, 8:00 AM - Friday, November 15, 2024, 11:59 PM

AMA PRA Category 1 Credits™ (3.25 hours), AMA PRA Category 1 Credits™ Designated (3.25 hours)

This online webinar provides an update on the diagnostic criteria based on the cytogenetic and genomics of multiple myeloma, benefits and risks of frontline therapy, consolidation, and maintenance therapy options, sequencing therapies, CAR-modified T-cell therapy, bispecific antibody constructs, and antibody-drug conjugate (ADC) based treatment for patients with multiple myeloma.

There are no fees to participate in the activity. Participants must review all activity contents, including the learning objectives, disclosure statements, and post activity assessment to receive CME credit for participation.

Contact Information

Brian Waggoner, Program Manager
MedNet, LLC
[email protected]

1. Outline the pathophysiology and diagnostic criteria based on the cytogenetic, and genomics of MM;
2. Identify the benefits and risks of frontline therapy for patients with MM;
3. Customize the consolidation and maintenance therapy options for patients with MM;
4. Summarize the role of sequencing therapies in relapsed and refractory patients with MM;
5. Recognize the role of B-cell maturation antigen (BCMA) as a therapeutic target for patients with MM;
6. Appraise the advantages of CAR-modified T-cell therapy for patients with MM;
7. Cite the efficacy and safety of bispecific antibody constructs in the treatment of patients with MM;
8. Incorporate the antibody-drug conjugate (ADC) based therapy for patients with MM.

PHYSICIAN CREDIT (ACCME)
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and MedNet, LLC. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

The University of Cincinnati designates this enduring material activity for a maximum of 3.25 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSES CREDIT (ANCC)
Amedco, a CME/CE company, and MedNet jointly sponsor this activity. Amedco is jointly accredited by the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. MedNet, the medical education company, serves as a content and logistic provider for this activity.

Amedco designates this webinar for a maximum of 3.25 ANCC contact hours for nurses.

NURSE PRACTIONERS CREDIT
The American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors and allow reciprocity for AANPCP continuing education credit. Maximum of 3.25 hours.

PHYSICIAN ASSISTANT/ASSOCIATES CREDIT
PAs may claim a maximum of 3.25 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit(s)^TM from organizations accredited by ACCME or a recognized state medical society.

COI / Disclosure of Relationships with Ineligible Entities

In accordance with the ACCME Standards for Integrity and Independence Integrity and Independence in Accredited Continuing Education and the University of Cincinnati policy, all faculty, planning committee members, and other individuals, who are in a position to control content, are required to disclose all relationships with ineligible companies* (commercial interests) within the last 24-months. All educational materials are reviewed for fair balance, scientific objectivity, and levels of evidence. The ACCME requires us to disqualify individuals who refuse to provide this information from involvement in the planning and implementation of accredited continuing education, or whose conflicts of interests cannot be mitigated.

*Companies that are ineligible to be accredited in the ACCME System (ineligible companies) are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant relationships have been mitigated. The University of Cincinnati, MedNet, Amedco, and the peer/content reviewers for this activity have no relevant conflict of interest to report.

Medical Director & Program Planners

MedNet, LLC
Kamatham A. Naidu, PhD
Brian Waggoner

University of Cincinnati, Center for Continuous Professional Development (CME)
Susan P. Tyler, PhD, Associate Dean
Heather Muskopf, Program Director
Elizabeth Shaughnessy, MD, Peer Reviewer

Amedco
Sheryl Morgan

Off-Label Disclosure Statement
Faculty members are required to inform the audience when they are discussing off-label, unapproved uses of devices and drugs. Physicians should consult full prescribing information before using any product mentioned during this educational activity.

Disclaimer Statement
The opinions expressed during this educational activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati, MedNet, LLC, and Amedco. The information is presented for the purpose of advancing the attendees’ professional development.

COI / Disclosure of Relationships with Ineligible Entities

In accordance with the ACCME Standards for Integrity and Independence Integrity and Independence in Accredited Continuing Education and the University of Cincinnati policy, all faculty, planning committee members, and other individuals, who are in a position to control content, are required to disclose all relationships with ineligible companies* (commercial interests) within the last 24-months. All educational materials are reviewed for fair balance, scientific objectivity, and levels of evidence. The ACCME requires us to disqualify individuals who refuse to provide this information from involvement in the planning and implementation of accredited continuing education, or whose conflicts of interests cannot be mitigated.

*Companies that are ineligible to be accredited in the ACCME System (ineligible companies) are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant relationships have been mitigated. The following disclosures were made:

Gareth J. Morgan, MD, PhD
Professor of Medicine and Director Myeloma Research
Perlmutter Cancer Center
NYU Langone Health
New York, NY

Dr. Morgan does not have any financial relationships to disclose.

Shaji Kumar, MD
Mark and Judy Mullins Professor of Hematological Malignancies
Mayo Clinic
Rochester, MN

Dr. Kumar discloses that he is a consultant for AbbVie, BMS, Genentech/Roche, Takeda, Janssen, Sanofi, Arcellx, K36, BeiGene; received research support from AbbVie, BMS, Genentech/Roche, Takeda, Janssen, Carsgen

Cesar Rodriguez, MD
Associate Professor of Medicine
The Tisch Cancer Institute
Icahn School of Medicine at Mount Sinai
Division of Hematology/Medical Oncology
New York, NY

Dr. Rodriguez discloses that he is a consultant for Janssen, BMS, Takeda, Sanofi, and Artiva

Saad Z. Usmani, MD
Chief, Myeloma Service
Memorial Sloan Kettering Cancer Center
New York, NY

Dr. Usmani discloses that he is a consultant/advisor for AbbVie, Amgen, and BMS; received research support from AbbVie, Amgen, Array Biopharma, and BMS

Nikhil C. Munshi, MD
Professor, Medicine
Harvard Medical School
Associate Professor, Medical Oncology
Dana-Farber Cancer Institute
Boston, MA

Dr. Munshi discloses that he is a consultant for AbbVie, Adaptive Biotech, Amgen, BMS, Celgene, GSK, Janssen, Karyopharm, Legend, Novartis, OncoPe, Pfizer, and Takeda; stock shareholder in OncoPep

Al-Ola Abdallah, MD
Associate Professor of Internal Medicine
Division of Hematologic Malignancies & Cellular Therapeutics
University of Kansas Medical Center
Kansas City, KS

Dr. Abdallah does not have any financial relationships to disclose

 

Mitigation of Relevant Financial Relationships

The University of Cincinnati adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests) over the last 24-months. All relevant relationships have been mitigated prior to the commencement of the activity.

Information regarding the new updated ACCME Standards for Integrity and Independence in Accredited Continuing Education can be found on the ACCME website.

 

This activity is supported by an independent educational grant from Sanofi.